Ng R P, Moran C J, Alexopoulos C G, Bellingham A J
Lancet. 1975 Nov 8;2(7941):901-3. doi: 10.1016/s0140-6736(75)92131-5.
In a controlled studiy, six patients with stage-IV Hodgkin's disease were given transfer factor (T.F.) prepared from patients with Hodgkin's disease in long remission. There was an apparent increase in cell-mediated immune responses as evidenced by a significant increase in the recipients' lymphocyte responses to phytohaemagglutinin stimulation. Three out of six patients converted to positive delayed-hypersensitivity tests. These three all had the nodular sclerosing type of Hodgkin's disease. These results warrant the further investigation of the use of Hodgkin's disease-specific T.F. as a therapeutic agent in this condition.
在一项对照研究中,6例IV期霍奇金病患者接受了从长期缓解的霍奇金病患者制备的转移因子(T.F.)。细胞介导的免疫反应明显增强,表现为受体淋巴细胞对植物血凝素刺激的反应显著增加。6例患者中有3例迟发型超敏反应试验转为阳性。这3例均为结节硬化型霍奇金病。这些结果有必要进一步研究将霍奇金病特异性转移因子用作这种疾病的治疗剂。